Table 1 Demographic, Clinical, and Pathologic Characteristics of 20 men with biochemical recurrent prostate cancer after previous therapy
Patient No. | Age (yr.) | Race | Serum PSA at Initial Diagnosis (ng/ml) | Gleason Score at Initial Diagnosis | Clinical Stage at Initial Diagnosis | Initial Treatment | Length of F/U months |
|---|---|---|---|---|---|---|---|
1 | 62 | White | UNK | 3+4 = 7 | T3aNxMx | RP | 12 |
2 | 67 | White | 4.8 | 3+3 = 6 | T2xNxMx | Brachy/EBRT/ADT | 12 |
3 | 67 | White | UNK | 3+3 = 6 | T2xNxMx | RP | 12 |
4 | 78 | White | 4.7 | 3+4 = 7 | T2aNxMx | Brachy/EBRT/ADT | 6, started ADT |
5 | 77 | African American | 14.08 | UNK | T3aNxMx | RP/EBRT | 12 |
6 | 75 | White | 8.28 | 4+5 = 9 | T2cNxMx | ADT/RP | 12 |
7 | 69 | White | 10.36 | 3+3 = 6 | T1cNxMx | EBRT | 12 |
8 | 71 | White | UNK | UNK | UNK | RP/Salvage EBRT | 12 |
9 | 75 | White | UNK | 4+4 = 8 | T2bNxMx | EBRT/ADT | 12 |
10 | 77 | White | 8.1 | 4+5 = 9 | T3bNxMx | RP | 3, started ADT |
11* | 79 | White | UNK | 2+3 = 5 | T1cNxMx | EBRT | 9, withdrew due to side effects |
12 | 68 | White | UNK | 4+4 = 8 | T2aNxMx | RP/Adjuvant EBRT | 6, started ADT |
13 | 76 | African American | 11.13 | 3+3 = 6 | T2aNxMx | EBRT | 12 |
14 | 79 | White | 4.0 | 3+4 = 7 | T1cNxMx | RP/Adjuvant EBRT | 12 |
15 | 73 | White | 10 | 3+2 = 5 | T1cNxMx | EBRT | 12 |
16 | 60 | White | 9.2 | 3+4 = 7 | T1cNxMx | RP/Adjuvant EBRT | 12 |
17 | 63 | White | 17.3 | 4+3 = 7 | T1cNxMx | EBRT | 12 |
18 | 70 | White | 9.8 | 3+3 = 6 | T2xNxMx | RP/salvage EBRT | 12 |
19* | 76 | African American | 4.1 | 3+4 = 7 | T2bNxMx | RP | 6, lost to F/U |
20 | 77 | White | 8.7 | UNK | T2aNxMx | EBRT | 6, lost to F/U |
Median | 73 | --- | 9.2 | 7 | --- | --- | 12 |